Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future
Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the r...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/full |
| _version_ | 1797730961661624320 |
|---|---|
| author | Eva Rihackova Michal Rihacek Michal Rihacek Michal Rihacek Maria Vyskocilova Dalibor Valik Dalibor Valik Dalibor Valik Lubomir Elbl |
| author_facet | Eva Rihackova Michal Rihacek Michal Rihacek Michal Rihacek Maria Vyskocilova Dalibor Valik Dalibor Valik Dalibor Valik Lubomir Elbl |
| author_sort | Eva Rihackova |
| collection | DOAJ |
| description | Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology. |
| first_indexed | 2024-03-12T11:51:42Z |
| format | Article |
| id | doaj.art-91e4c0080c264fac809b97e86a95d172 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-12T11:51:42Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-91e4c0080c264fac809b97e86a95d1722023-08-31T06:41:33ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-08-011010.3389/fcvm.2023.12435311243531Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the futureEva Rihackova0Michal Rihacek1Michal Rihacek2Michal Rihacek3Maria Vyskocilova4Dalibor Valik5Dalibor Valik6Dalibor Valik7Lubomir Elbl8Department of Internal Medicine and Cardiology, University Hospital Brno and Faculty of Medicine of Masaryk University, Brno, Czech RepublicDepartment of Laboratory Medicine, University Hospital Brno, Brno, Czech RepublicDepartment of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech RepublicDepartment of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech RepublicDepartment of Internal Medicine and Cardiology, University Hospital Brno and Faculty of Medicine of Masaryk University, Brno, Czech RepublicDepartment of Laboratory Medicine, University Hospital Brno, Brno, Czech RepublicDepartment of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech RepublicDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech RepublicDepartment of Internal Medicine and Cardiology, University Hospital Brno and Faculty of Medicine of Masaryk University, Brno, Czech RepublicTreatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/fulllymphomacardiotoxicitychemotherapymodern treatmentpreventioncardiac adverse events |
| spellingShingle | Eva Rihackova Michal Rihacek Michal Rihacek Michal Rihacek Maria Vyskocilova Dalibor Valik Dalibor Valik Dalibor Valik Lubomir Elbl Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future Frontiers in Cardiovascular Medicine lymphoma cardiotoxicity chemotherapy modern treatment prevention cardiac adverse events |
| title | Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future |
| title_full | Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future |
| title_fullStr | Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future |
| title_full_unstemmed | Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future |
| title_short | Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future |
| title_sort | revisiting treatment related cardiotoxicity in patients with malignant lymphoma a review and prospects for the future |
| topic | lymphoma cardiotoxicity chemotherapy modern treatment prevention cardiac adverse events |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/full |
| work_keys_str_mv | AT evarihackova revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture AT michalrihacek revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture AT michalrihacek revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture AT michalrihacek revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture AT mariavyskocilova revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture AT daliborvalik revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture AT daliborvalik revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture AT daliborvalik revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture AT lubomirelbl revisitingtreatmentrelatedcardiotoxicityinpatientswithmalignantlymphomaareviewandprospectsforthefuture |